



NDA 208558

**NDA APPROVAL**

AstraZeneca Pharmaceuticals LP  
Attention: Karen McCullough, PhD  
Director, Global Regulatory Affairs Oncology  
One MedImmune Way  
Gaithersburg, MD 20878

Dear Dr. McCullough:

Please refer to your New Drug Application (NDA) dated February 22, 2017, received February 22, 2017, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lynparza<sup>®</sup> (olaparib) tablets, 100 mg and 150 mg.

This new drug application provides for the use of Lynparza<sup>®</sup> (olaparib) tablets as monotherapy:

- for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and
- for the treatment of adult patients with deleterious or suspected deleterious germline *BRCA*-mutated (*gBRCAm*) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

A shelf life of 36 months is granted [REDACTED] (b) (4) [REDACTED] (b) (4) for both the 100 mg and 150 mg tablets when stored in the HDPE bottle configuration with desiccants under the labeled conditions of “Store at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].”

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content

of labeling must be identical to the enclosed labeling (text for the package insert and medication guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

### **IMMEDIATE CONTAINER LABELS**

Submit final printed immediate container labels that are identical to the enclosed immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission “**Final Printed Container Labels for approved NDA 208558.**” Approval of this submission by FDA is not required before the labeling is used.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because necessary studies are impossible or highly impracticable since ovarian cancer does not occur in children.

### **POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

We remind you of your postmarketing commitments:

- 3238-1 Submit the progression-free survival (PFS) and molecular characteristics (patient and tumor) final report, labeling, and datasets from clinical trial D0816C00020, entitled, “OPINION - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy.”

The timetable you submitted on August 9, 2017, states that you will conduct this study according to the following schedule:

Draft Protocol Submission:	08/2017
Final Protocol Submission:	11/2017
Trial Completion:	12/2020
Final Report Submission:	06/2021

3238-2 Submit the overall response rate (ORR) and duration of response (DOR) analyses with datasets from clinical trial D0816C00010 (SOLO-3), entitled, "A Randomized Trial Establishing the Superiority of Olaparib over Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Deleterious or Suspected Deleterious Germline *BRCA1/2* Mutations."

The timetable you submitted on August 11, 2017, states that you will conduct this study according to the following schedule:

Draft Protocol (Amendment) Submission:	10/2017
Draft Statistical Analysis Plan Submission:	11/2017
Final Protocol Submission:	12/2017
Trial Completion:	02/2019
Final Report Submission:	08/2019

3238-3 Submit the overall survival (OS) analyses with datasets from clinical trial D0818C00002, SOLO-2, the ongoing randomized double-blind, placebo-controlled, multi-center trial to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum-based chemotherapy.

The timetable you submitted on August 14, 2017, states that you will conduct this study according to the following schedule:

Trial Completion:	06/2019
Final Report Submission:	12/2019

Submit clinical protocols to your IND 075918 for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii) you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing

commitments should be prominently labeled **“Postmarketing Commitment Protocol,”** **“Postmarketing Commitment Final Report,”** or **“Postmarketing Commitment Correspondence.”**

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert, Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Rajesh Venugopal, Senior Regulatory Project Manager, at (301) 796-4730.

Sincerely,

*{See appended electronic signature page}*

Julia Beaver, MD  
Acting Director  
Division of Oncology Products 1  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

Enclosure(s):  
Content of Labeling  
Container Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

JULIA A BEAVER  
08/17/2017